RT Journal Article SR Electronic T1 Maximising information on smell, quantitative motor impairment and probable REM-sleep behaviour disorder in the prediction of Parkinson’s disease JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.03.03.20023994 DO 10.1101/2020.03.03.20023994 A1 Jonathan P. Bestwick A1 Stephen D. Auger A1 Anette E. Schrag A1 Donald G Grosset A1 Sofia Kanavou A1 Gavin Giovannoni A1 Andrew J. Lees A1 Jack Cuzick A1 Alastair J. Noyce YR 2020 UL http://medrxiv.org/content/early/2020/03/06/2020.03.03.20023994.abstract AB Background Hyposmia, motor impairment and probable REM-sleep behaviour disorder (RBD) are markers for Parkinson’s disease (PD). Proposed PD risk prediction models have dichotomised test results and applied likelihood ratios (LRs) to scores above and below cut-offs. We investigate whether LRs for specific test values could enhance prediction models.Methods Smell and probable RBD data for PD patients were taken from the Tracking Parkinson’s study (n=1046). For motor impairment previously published data were supplemented (n=87). PREDICT-PD pilot study participants were the controls. Smell, motor impairment and RBD were assessed using the University of Pennsylvania Smell Identification Test (UPSIT), the Bradykinesia-Akinesia Incoordination (BRAIN) test and the REM sleep behaviour disorder Screening Questionnaire (RBDSQ). UPSIT and RBDSQ data were analysed using logistic regression to determine which items were predictive of PD, or using total scores. Gaussian distributions were fitted to BRAIN test scores. LRs were calculated from logistic regression models or from score distributions. False-positive rates (FPRs) for specified detection rates (DRs) were calculated.Results Logistic regression modelling yielded a greater range of LRs. 16 odours were associated with PD; LRs ranged from 0.005-5511. 6 RBDSQ questions were associated with PD; LRs ranged from from 0.34-69. BRAIN test LRs ranged from 0.16-1311. For a 70% DR the FPR for the 16 odours was 2.4%, for 50% DRs, the BRAIN test FPR was 6.6% and 12.2% for the RBDSQ.Conclusions Maximising information on PD markers can potentially improve the ability of algorithms to detect PD by generating LRs with a larger range of values than using dichotomised results.Competing Interest StatementThe authors have declared no competing interest.Funding StatementBoth the PREDICT-PD and Tracking Parkinson’s studies are funded by Parkinson’s UK Dr Alastair Noyce - Dr. Noyce is funded by the Barts Charity. Dr. Noyce reports additional grants from Parkinson's UK, Virginia Kieley benefaction, UCL-Movement Disorders Centre, grants and non-financial support from GE Healthcare, and personal fees from LEK, Guidepoint, Profile, Roche, Biogen Bial and Britannia, outside the submitted work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIt is the intention of the authors to make study data available for sharing